0.3204
price up icon5.39%   0.0164
after-market After Hours: .33 0.0096 +3.00%
loading
Athira Pharma Inc stock is traded at $0.3204, with a volume of 170.26K. It is up +5.39% in the last 24 hours and up +17.79% over the past month. Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
See More
Previous Close:
$0.304
Open:
$0.315
24h Volume:
170.26K
Relative Volume:
0.32
Market Cap:
$12.92M
Revenue:
-
Net Income/Loss:
$-117.67M
P/E Ratio:
-0.1037
EPS:
-3.09
Net Cash Flow:
$-101.06M
1W Performance:
-3.20%
1M Performance:
+17.79%
6M Performance:
-44.51%
1Y Performance:
-87.39%
1-Day Range:
Value
$0.305
$0.35
1-Week Range:
Value
$0.295
$0.35
52-Week Range:
Value
$0.2195
$3.67

Athira Pharma Inc Stock (ATHA) Company Profile

Name
Name
Athira Pharma Inc
Name
Phone
(425) 620-8501
Name
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Name
Employee
26
Name
Twitter
Name
Next Earnings Date
2024-12-07
Name
Latest SEC Filings
Name
ATHA's Discussions on Twitter

Compare ATHA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ATHA
Athira Pharma Inc
0.3204 12.92M 0 -117.67M -101.06M -3.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.91 114.57B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
522.68 55.88B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
308.78 39.64B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
551.22 35.64B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
264.42 28.55B 3.81B -644.79M -669.77M -6.24

Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-19-24 Downgrade Mizuho Outperform → Neutral
Sep-04-24 Downgrade BTIG Research Buy → Neutral
Sep-04-24 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-04-24 Downgrade Rodman & Renshaw Buy → Neutral
Aug-19-24 Initiated Rodman & Renshaw Buy
Oct-17-22 Upgrade JMP Securities Mkt Perform → Mkt Outperform
Jul-07-22 Initiated Mizuho Buy
Jun-23-22 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-23-22 Downgrade Jefferies Buy → Hold
Jun-23-22 Downgrade Stifel Buy → Hold
May-10-22 Initiated BTIG Research Buy
Apr-21-22 Initiated Berenberg Buy
Dec-15-21 Initiated Goldman Neutral
Oct-13-20 Initiated Goldman Buy
Oct-13-20 Initiated JMP Securities Mkt Outperform
Oct-13-20 Initiated Jefferies Buy
Oct-13-20 Initiated Stifel Buy
View All

Athira Pharma Inc Stock (ATHA) Latest News

pulisher
Jun 08, 2025

Two Sigma Advisers LP Has $149,000 Position in Athira Pharma, Inc. (NASDAQ:ATHA) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

ATHA LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Athira Pharma, Inc. Investors with LARGE LOSSES to Secure Counsel Before Important Deadline in Securities Class Action – ATHA - ACCESS Newswire

Jun 07, 2025
pulisher
Jun 05, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jun 05, 2025
pulisher
Jun 05, 2025

Athira Pharma (NASDAQ:ATHA) Trading 9.2% Higher – Here’s Why - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

HAGENS BERMAN, NATIONAL ATTORNEYS, Alerts Athira Pharma (ATHA) Investors to Filing Of Securities Class Action, Advises Investors with Losses to Contact Firm's Attorneys Now - ACCESS Newswire

Jun 04, 2025
pulisher
Jun 03, 2025

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022 - Barchart.com

Jun 03, 2025
pulisher
Jun 02, 2025

Athira Pharma Holds Annual Stockholders Meeting - TipRanks

Jun 02, 2025
pulisher
Jun 01, 2025

Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022 - Barchart.com

Jun 01, 2025
pulisher
May 23, 2025

Athira Pharma (ATHA) Is Paying a $10M Settlement to Investors — Here’s How to Get Your Share - TradingView

May 23, 2025
pulisher
May 20, 2025

Athira Pharma’s SWOT analysis: als drug developer’s stock faces pivotal phase - Investing.com

May 20, 2025
pulisher
May 15, 2025

Athira Pharma (ATHA) Highlights Promising Phase 1 Results for ALS Drug Candidate | ATHA Stock News - GuruFocus

May 15, 2025
pulisher
May 14, 2025

Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105 - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Athira Pharma (ATHA) Projected to Post Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 14, 2025

Athira Pharma Reports Reduced Losses and Strategic Focus - MSN

May 14, 2025
pulisher
May 13, 2025

Athira Pharma to Present Data from First-in-Human Phase 1 Clinic - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Athira Pharma to Present Data from First-in-Human Phase 1 - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

Breakthrough ALS Drug ATH-1105 Achieves Key Safety Milestones, Targets Patient Trials Late 2025 - Stock Titan

May 13, 2025
pulisher
May 10, 2025

Athira Pharma Reports First Quarter 2025 Financial Results and P - GuruFocus

May 10, 2025
pulisher
May 09, 2025

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates - The Manila Times

May 09, 2025
pulisher
May 08, 2025

Athira Pharma, Inc. (NASDAQ:ATHA) Position Lowered by Renaissance Technologies LLC - Defense World

May 08, 2025
pulisher
May 07, 2025

Athira Pharma Slides As Insider Purchases Lose Another US$89k - simplywall.st

May 07, 2025
pulisher
May 06, 2025

Head-To-Head Review: NKGen Biotech (NYSE:NKGN) and Athira Pharma (NASDAQ:ATHA) - Defense World

May 06, 2025
pulisher
Apr 24, 2025

ATHAAthira Pharma, Inc. Latest Stock News & Market Updates - Stock Titan

Apr 24, 2025
pulisher
Apr 17, 2025

Athira Pharma shifts to Nasdaq Capital Market amid compliance bid By Investing.com - Investing.com India

Apr 17, 2025
pulisher
Apr 16, 2025

Athira Pharma shifts to Nasdaq Capital Market amid compliance bid - Investing.com Australia

Apr 16, 2025
pulisher
Apr 07, 2025

Athira Pharma stock plunges to 52-week low of $0.25 - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

Athira Pharma stock plunges to 52-week low of $0.25 By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 04, 2025

SEC Form PRE 14A filed by Athira Pharma Inc. - Quantisnow

Apr 04, 2025
pulisher
Mar 28, 2025

Athira Pharma stock hits 52-week low at $0.3 amid steep decline - Investing.com India

Mar 28, 2025
pulisher
Mar 27, 2025

Athira Pharma stock hits 52-week low at $0.3 amid steep decline By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 13, 2025

What is ATHA’s price-to-sales ratio telling us about the company’s value? - US Post News

Mar 13, 2025
pulisher
Mar 11, 2025

Athira Pharma: Hold Rating Amid Strategic Uncertainty and Resource Challenges - TipRanks

Mar 11, 2025
pulisher
Mar 10, 2025

Athira Pharma stock hits 52-week low at $0.33 amid steep decline - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

Athira Pharma stock hits 52-week low at $0.33 amid steep decline By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 07, 2025

Athira Pharma Stock Price, Quotes and Forecasts | NASDAQ:ATHA - Benzinga

Mar 07, 2025
pulisher
Mar 03, 2025

Athira Pharma’s Strategic Focus on ATH-1105 Amidst Uncertainties: Hold Rating Maintained - TipRanks

Mar 03, 2025
pulisher
Mar 02, 2025

Athira Pharma’s 2024 Financial Results and Pipeline Progress - MSN

Mar 02, 2025
pulisher
Feb 27, 2025

Athira Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

Athira Pharma, Inc. SEC 10-K Report - TradingView

Feb 27, 2025
pulisher
Feb 26, 2025

Athira Pharma stock hits 52-week low at $0.41 amid steep decline - Investing.com Australia

Feb 26, 2025
pulisher
Feb 25, 2025

Athira Pharma stock hits 52-week low at $0.41 amid steep decline By Investing.com - Investing.com South Africa

Feb 25, 2025

Athira Pharma Inc Stock (ATHA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Athira Pharma Inc Stock (ATHA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
San Martin Javier
CHIEF MEDICAL OFFICER
Jan 02 '25
Sale
0.56
10,826
6,083
35,841
Litton Mark James
President and CEO
Dec 31 '24
Option Exercise
0.00
108,333
0
267,698
Litton Mark James
President and CEO
Jan 02 '25
Sale
0.56
25,107
14,108
242,591
CHURCH KEVIN
CHIEF SCIENTIFIC OFFICER
Dec 31 '24
Option Exercise
0.00
36,667
0
139,271
CHURCH KEVIN
CHIEF SCIENTIFIC OFFICER
Jan 02 '25
Sale
0.56
8,510
4,782
130,761
Renninger Robert
VP of Finance
Dec 31 '24
Option Exercise
0.00
12,359
0
92,605
Renninger Robert
VP of Finance
Jan 02 '25
Sale
0.56
2,881
1,619
89,724
Worthington Mark
General Counsel and CCO
Dec 31 '24
Option Exercise
0.00
36,667
0
92,245
Worthington Mark
General Counsel and CCO
Jan 02 '25
Sale
0.56
8,510
4,782
83,735
$71.22
price up icon 5.12%
$22.86
price up icon 0.18%
$35.10
price up icon 0.75%
$19.95
price up icon 0.86%
$106.33
price down icon 0.23%
biotechnology ONC
$264.42
price down icon 1.93%
Cap:     |  Volume (24h):